JM Ruiz-Moreno, F Gomez-Ulla, JA Montero, S … - Eye, 2009 - phx1.medscape.com New antiangiogenic drugs have been made available to treat subfoveal CNV
secondary to high myopia, although there have not been too many reports yet.
[11-20] The purpose of this pilot study is to evaluate the outcome of ... Cited by 16 - Related articles - All 8 versions
L Konstantinidis, I Mantel, JAC Pournaras, L … - Graefe's Archive for Clinical and Experimental …, 2009 - Springer Abstract Background Macular choroidal neovascularization (CNV) is one of the
most vision-threatening complications of myopia, which can lead to severe vision
loss. The purpose of this study was to evaluate the safety and efficacy of ... Cited by 6 - Related articles - All 2 versions
- ►prsjournal.com JM Ruiz-Moreno, JA Montero, F Gomez-Ulla, … - British Journal of Ophthalmology, 2009 - bjo.bmj.com Results: The average age was 50 (SD 15, range 29–82) years. The mean LogMAR
BCVA at baseline was 0.55 (SD 0.25, range 0.2–1.0) and 0.38 (SD 0.32, range
0.0–1.2) at 1 year. Sixteen eyes were naïve for treatment and 13 eyes ... Cited by 2 - Related articles - All 4 versions